Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBT001 in Healthy Volunteers and Atopic Dermatitis Patients
NCT07239947Phase 1Recruiting
- Sponsor
- Bambusa Therapeutics
- Start
- Aug 2025
- Primary completion
- Dec 2027
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BBT001 in atopic dermatitis (AD) (4 arms), sponsored by Bambusa Therapeutics. Primary endpoints: Number of participants with adverse events at Day 169, Change in vital sign measurements at Day 169 and 3 more. Started Aug 2025; status: recruiting.
02
Drugs
BBT001
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07239947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07239947.